TAF7

Summary

TAF7 (TATA-box binding protein associated factor 7, HGNC:11541) is a protein-coding gene on chromosome 5q31.3, encoding Transcription initiation factor TFIID subunit 7 (Q15545). The TFIID basal transcription factor complex plays a major role in the initiation of RNA polymerase II (Pol II)-dependent transcription. It is a common-essential gene (DepMap: required in 95.9% of cancer cell lines).

The intronless gene for this transcription coactivator is located between the protocadherin beta and gamma gene clusters on chromosome 5. The protein encoded by this gene is a component of the TFIID protein complex, a complex which binds to the TATA box in class II promoters and recruits RNA polymerase II and other factors. This particular subunit interacts with the largest TFIID subunit, as well as multiple transcription activators. The protein is required for transcription by promoters targeted by RNA polymerase II.

Source: NCBI Gene 6879 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 42 total
• Cancer dependency (DepMap): dependent in 95.9% of screened cell lines (common-essential)
• MANE Select transcript: NM_005642

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11541
Approved symbol	TAF7
Name	TATA-box binding protein associated factor 7
Location	5q31.3
Locus type	gene with protein product
Status	Approved
Aliases	TAFII55
Ensembl gene	ENSG00000178913
Ensembl biotype	protein_coding
OMIM	600573
Entrez	6879

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 2 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000313368, ENST00000624699, ENST00000624761, ENST00000686518

RefSeq mRNA: 1 — MANE Select: NM_005642 NM_005642

CCDS: CCDS4259

Canonical transcript exons

ENST00000313368 — 1 exons

Exon	Start	End
ENSE00001388076	141318490	141320784

Expression profiles

Bgee: expression breadth ubiquitous, 300 present calls, max score 98.18.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 59.7209 / max 527.0253, expressed in 1815 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
63840	59.7209	1815

Top tissues by expression

301 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	98.18	gold quality
ganglionic eminence	UBERON:0004023	97.86	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	97.83	gold quality
biceps brachii	UBERON:0001507	97.71	gold quality
islet of Langerhans	UBERON:0000006	97.70	gold quality
ventricular zone	UBERON:0003053	97.69	gold quality
cortical plate	UBERON:0005343	97.65	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	97.54	gold quality
gastrocnemius	UBERON:0001388	97.26	gold quality
muscle of leg	UBERON:0001383	97.23	gold quality
muscle organ	UBERON:0001630	97.15	gold quality
skeletal muscle organ	UBERON:0014892	97.15	gold quality
choroid plexus epithelium	UBERON:0003911	97.14	gold quality
heart right ventricle	UBERON:0002080	97.06	gold quality
vastus lateralis	UBERON:0001379	96.99	gold quality
quadriceps femoris	UBERON:0001377	96.91	gold quality
skeletal muscle tissue	UBERON:0001134	96.88	gold quality
epithelium of nasopharynx	UBERON:0001951	96.72	gold quality
nasopharynx	UBERON:0001728	96.70	gold quality
right uterine tube	UBERON:0001302	96.69	gold quality
deltoid	UBERON:0001476	96.67	gold quality
hindlimb stylopod muscle	UBERON:0004252	96.67	gold quality
lymph node	UBERON:0000029	96.58	gold quality
heart left ventricle	UBERON:0002084	96.49	gold quality
skin of hip	UBERON:0001554	96.48	gold quality
cardiac ventricle	UBERON:0002082	96.48	gold quality
left ovary	UBERON:0002119	96.35	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	96.32	gold quality
muscle tissue	UBERON:0002385	96.32	gold quality
triceps brachii	UBERON:0001509	96.31	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-10485	yes	1946.64
E-GEOD-100618	no	997.80
E-CURD-122	no	9.35
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AP1, IRF6, SP1, TAF1, TBP, TBPL1, TFAP2A, YBX1

miRNA regulators (miRDB)

37 targeting TAF7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-9718	99.94	68.91	918
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-7157-5P	99.66	69.33	1829
HSA-MIR-4499	99.62	67.29	1470
HSA-MIR-3685	99.62	68.83	1621
HSA-MIR-4261	99.59	70.30	3415
HSA-MIR-4310	99.59	68.84	2527
HSA-MIR-147B-5P	99.45	70.62	2432
HSA-MIR-103A-1-5P	99.39	67.78	1545
HSA-MIR-103A-2-5P	99.39	67.72	1577
HSA-MIR-6507-3P	99.35	67.32	1059
HSA-MIR-3978	99.24	68.39	2201
HSA-MIR-155-3P	99.03	67.99	924
HSA-MIR-5701	98.97	69.54	1502
HSA-MIR-153-3P	98.96	72.51	1644
HSA-MIR-5001-3P	98.91	67.28	1394
HSA-MIR-3124-3P	98.87	68.95	2123
HSA-MIR-519A-2-5P	98.78	71.74	1401
HSA-MIR-520B-5P	98.78	71.74	1401
HSA-MIR-6818-3P	98.56	68.23	1307
HSA-MIR-3928-5P	98.50	67.48	980
HSA-MIR-6806-3P	98.50	67.31	980
HSA-MIR-628-5P	98.36	67.74	844
HSA-MIR-4684-5P	98.29	67.99	1650

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 95.9% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 16)

• TAF7 represents a novel c-Jun co-activator mediating activation of AP-1 target genes in response to extracellular signals (PMID:12676957)
• TAF7 has a role as a basal regulator for mammalian polyamine transport activity and MGBG-induced apoptosis (PMID:15078871)
• Functions as a check-point regulator suppressing premature transcription initiation until preinitiation complex assembly is complete. (PMID:16407123)
• These results suggest normal TBP-binding interactions–specifically recognition, stability, and conformation-are disrupted by CldAMP insertion into eukaryotic promoter sequences. (PMID:17320040)
• TAF7 interacts with the transcription factors, TFIIH and P-TEFb, resulting in the inhibition of their Pol II CTD kinase activities (PMID:18391197)
• TAF7, until now considered only a TFIID component and regulator of TAF1-dependent transcription, also regulates TAF1-independent transcription (PMID:20937824)
• analysis of phosphorylation-dependent regulation of cyclin D1 and cyclin A gene transcription by TFIID subunits TAF1 and TAF7 (PMID:22711989)
• three CTD kinases, CDK7, CDK9, and BRD4, engage in cross-talk, modulating their subsequent C-terminal domain phosphorylation, and also phosphorylate TAF7 (PMID:23027873)
• the surface of the TAF1-TAF7 complex contains two prominent conserved surface pockets, one of which binds selectively to an inhibitory trimethylated histone H3 (PMID:24927529)
• These results resolve the structural organization of the TAF1-TAF7 module in TFIID and unveil a critical promoter-binding function of TAF1 in transcription regulation. (PMID:25412659)
• the MED26-NTD functions as a molecular switch in the exchange of TBP-associated factor 7 (TAF7) for LEC to facilitate the transition from initiation to elongation during transcription of a subset of snRNA genes (PMID:25575120)
• EAF1 (239-268) and TAF7 (205-235) peptide interactions were both mapped to the same groove formed by H3 and H4 helices of MED26 N-terminal domain. (PMID:28893534)
• TAF7, presumably its TFIID-independent form, binds the promoter and enhances the levels of Pol II at the gene body but not the promoter (PMID:30028080)
• MicroRNA-374c-5p inhibits the development of breast cancer through TATA-box binding protein associated factor 7-mediated transcriptional regulation of DEP domain containing 1. (PMID:31162714)
• Novel variations in spermatogenic transcription regulators RFX2 and TAF7 increase risk of azoospermia. (PMID:34762273)
• SETD7 Promotes Cell Proliferation and Migration via Methylation-mediated TAF7 in Clear Cell Renal Cell Carcinoma. (PMID:38904013)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	taf7	ENSDARG00000019572
mus_musculus	Taf7	ENSMUSG00000051316
rattus_norvegicus	Slc25a2	ENSRNOG00000068493
drosophila_melanogaster	Taf7	FBGN0024909
caenorhabditis_elegans		WBGENE00006388
caenorhabditis_elegans		WBGENE00006389

Paralogs (1): TAF7L (ENSG00000102387)

Protein

Protein identifiers

Transcription initiation factor TFIID subunit 7 — Q15545 (reviewed: Q15545)

Alternative names: RNA polymerase II TBP-associated factor subunit F, Transcription initiation factor TFIID 55 kDa subunit

All UniProt accessions (2): A0A096LPC3, Q15545

UniProt curated annotations — full annotation on UniProt →

Function. The TFIID basal transcription factor complex plays a major role in the initiation of RNA polymerase II (Pol II)-dependent transcription. TFIID recognizes and binds promoters with or without a TATA box via its subunit TBP, a TATA-box-binding protein, and promotes assembly of the pre-initiation complex (PIC). The TFIID complex consists of TBP and TBP-associated factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13. TAF7 forms a promoter DNA binding subcomplex of TFIID, together with TAF1 and TAF2. Part of a TFIID complex containing TAF10 (TFIID alpha) and a TFIID complex lacking TAF10 (TFIID beta).

Subunit / interactions. Component of the TFIID basal transcription factor complex, composed of TATA-box-binding protein TBP, and a number of TBP-associated factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13. Part of a TFIID-containing RNA polymerase II pre-initiation complex that is composed of TBP and at least GTF2A1, GTF2A2, GTF2E1, GTF2E2, GTF2F1, GTF2H2, GTF2H3, GTF2H4, GTF2H5, GTF2B, TCEA1, ERCC2, ERCC3, TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13. Interacts with TAF1; the interaction is direct. Interacts with TAF1, TAF5, TAF11, TAF12, and TAF13, but not with TAF10 or TBP. Component of some MLL1/MLL complex, at least composed of the core components KMT2A/MLL1, ASH2L, HCFC1/HCF1, WDR5 and RBBP5, as well as the facultative components BACC1, CHD8, E2F6, HSP70, INO80C, KANSL1, LAS1L, MAX, MCRS1, MGA, MYST1/MOF, PELP1, PHF20, PRP31, RING2, RUVB1/TIP49A, RUVB2/TIP49B, SENP3, TAF1, TAF4, TAF6, TAF7, TAF9 and TEX10. Interacts with CIITA and TAF1 and inhibits their acetyltransferase activity, and behaving as a repressor of CIITA- and TAF1-regulated promoters.

Subcellular location. Nucleus.

Tissue specificity. Ubiquitous.

Post-translational modifications. Phosphorylated by CIITA. Phosphorylation at Ser-264 by TAF1 in early G1 phase disrupts binding to TAF1. Ubiquitinated by TRIM26; leading to proteasomal degradation.

Domain organisation. The [KR]-[STA]-K motif is specifically recognized by the SETD7 methyltransferase, which methylates Lys-5 in vitro.

Miscellaneous. Overexpression of TAF7 in HeLa cells inhibits cyclin D1 and cyclin A gene transcription and causes the cells to accumulate in early S phase. In contrast, depletion of TAF7 from TFIID complexes by siRNAs increases histone H3 acetylation at both cyclin promoters and stimulates cyclins CCND1 and CCNA gene transcription.

Similarity. Belongs to the TAF7 family.

RefSeq proteins (1): NP_005633* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006751	TAFII55_prot_cons_reg	Domain
IPR037817	TAF7	Family

Pfam: PF04658

UniProt features (28 total): modified residue 5, strand 5, helix 5, region of interest 4, mutagenesis site 3, chain 1, sequence variant 1, sequence conflict 1, coiled-coil region 1, short sequence motif 1, compositionally biased region 1

Structure

Experimental structures (PDB)

28 structures.

PDB	Method	Resolution (Å)
4RGW	X-RAY DIFFRACTION	2.3
7EGH	ELECTRON MICROSCOPY	3.04
7EGB	ELECTRON MICROSCOPY	3.3
7EG9	ELECTRON MICROSCOPY	3.7
7EGC	ELECTRON MICROSCOPY	3.9
7ENA	ELECTRON MICROSCOPY	4.07
7EGA	ELECTRON MICROSCOPY	4.1
7ENC	ELECTRON MICROSCOPY	4.13
8GXS	ELECTRON MICROSCOPY	4.16
7EDX	ELECTRON MICROSCOPY	4.5
8GXQ	ELECTRON MICROSCOPY	5.04
8WAK	ELECTRON MICROSCOPY	5.47
8WAP	ELECTRON MICROSCOPY	5.85
8WAN	ELECTRON MICROSCOPY	6.07
8WAS	ELECTRON MICROSCOPY	6.13
7EG7	ELECTRON MICROSCOPY	6.2
8WAQ	ELECTRON MICROSCOPY	6.29
8WAO	ELECTRON MICROSCOPY	6.4
7EGD	ELECTRON MICROSCOPY	6.75
8WAR	ELECTRON MICROSCOPY	7.2
7EG8	ELECTRON MICROSCOPY	7.4
6MZM	ELECTRON MICROSCOPY	7.5
5FUR	ELECTRON MICROSCOPY	8.5
8WAL	ELECTRON MICROSCOPY	8.52
7EGJ	ELECTRON MICROSCOPY	8.64
7EGE	ELECTRON MICROSCOPY	9
7EGI	ELECTRON MICROSCOPY	9.82
6MZL	ELECTRON MICROSCOPY	23

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q15545-F1	76.41	0.46

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 201, 213, 264, 171, 200

Mutagenesis-validated functional residues (3):

Position	Phenotype
5	abolishes methylation in vitro.
264	reduced h3 acetylation and transcription at target promoters.
264	50% reduction in taf1-binding, reduced incorporation of taf7 into tfiid complexes.

Function

Pathways and Gene Ontology

Reactome pathways

20 pathways

ID	Pathway
R-HSA-167161	HIV Transcription Initiation
R-HSA-167162	RNA Polymerase II HIV Promoter Escape
R-HSA-167172	Transcription of the HIV genome
R-HSA-674695	RNA Polymerase II Pre-transcription Events
R-HSA-6804756	Regulation of TP53 Activity through Phosphorylation
R-HSA-73776	RNA Polymerase II Promoter Escape
R-HSA-73779	RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
R-HSA-75953	RNA Polymerase II Transcription Initiation
R-HSA-76042	RNA Polymerase II Transcription Initiation And Promoter Clearance
R-HSA-162587	HIV Life Cycle
R-HSA-162599	Late Phase of HIV Life Cycle
R-HSA-162906	HIV Infection
R-HSA-1643685	Disease
R-HSA-212436	Generic Transcription Pathway
R-HSA-3700989	Transcriptional Regulation by TP53
R-HSA-5633007	Regulation of TP53 Activity
R-HSA-5663205	Infectious disease
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)
R-HSA-9824446	Viral Infection Pathways

MSigDB gene sets: 231 (showing top): YAGI_AML_WITH_INV_16_TRANSLOCATION, GOBP_REGULATION_OF_PHOSPHORYLATION, GOBP_NEGATIVE_REGULATION_OF_KINASE_ACTIVITY, GOBP_CELLULAR_RESPONSE_TO_LIPID, MODULE_151, ENK_UV_RESPONSE_KERATINOCYTE_UP, GOBP_POSITIVE_REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_INITIATION, GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY, GOBP_REGULATION_OF_DNA_REPAIR, GOBP_HORMONE_MEDIATED_SIGNALING_PATHWAY, REACTOME_HIV_INFECTION, GOBP_CELLULAR_RESPONSE_TO_HORMONE_STIMULUS, MODULE_256, GOBP_REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_INITIATION, GOBP_NEGATIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS

GO Biological Process (18): negative regulation of transcription by RNA polymerase II (GO:0000122), spermine transport (GO:0000296), regulation of DNA repair (GO:0006282), chromatin organization (GO:0006325), DNA-templated transcription initiation (GO:0006352), regulation of transcription by RNA polymerase II (GO:0006357), transcription by RNA polymerase II (GO:0006366), transcription initiation at RNA polymerase II promoter (GO:0006367), negative regulation of protein kinase activity (GO:0006469), estrogen receptor signaling pathway (GO:0030520), mRNA transcription by RNA polymerase II (GO:0042789), negative regulation of MHC class I biosynthetic process (GO:0045344), negative regulation of MHC class II biosynthetic process (GO:0045347), negative regulation of DNA-templated transcription (GO:0045892), positive regulation of DNA-templated transcription (GO:0045893), positive regulation of transcription by RNA polymerase II (GO:0045944), RNA polymerase II preinitiation complex assembly (GO:0051123), positive regulation of transcription initiation by RNA polymerase II (GO:0060261)

GO Molecular Function (11): transcription cis-regulatory region binding (GO:0000976), TFIIH-class transcription factor complex binding (GO:0001097), RNA polymerase II general transcription initiation factor activity (GO:0016251), histone acetyltransferase binding (GO:0035035), nuclear vitamin D receptor binding (GO:0042809), nuclear thyroid hormone receptor binding (GO:0046966), protein heterodimerization activity (GO:0046982), P-TEFb complex binding (GO:0106140), DNA-binding transcription factor binding (GO:0140297), protein binding (GO:0005515), histone H3K27me3 reader activity (GO:0061628)

GO Cellular Component (8): male germ cell nucleus (GO:0001673), nucleus (GO:0005634), nucleoplasm (GO:0005654), transcription regulator complex (GO:0005667), transcription factor TFIID complex (GO:0005669), cytoplasm (GO:0005737), transcription factor TFTC complex (GO:0033276), MLL1 complex (GO:0071339)

Reactome top-level categories

Rollup of top-13 pathways:

Category	Pathways
RNA Polymerase II Transcription	4
Transcription of the HIV genome	2
RNA Polymerase II Transcription Initiation And Promoter Clearance	2
Late Phase of HIV Life Cycle	1
Regulation of TP53 Activity	1
HIV Infection	1
HIV Life Cycle	1
Viral Infection Pathways	1
Generic Transcription Pathway	1
Transcriptional Regulation by TP53	1
Disease	1
Gene expression (Transcription)	1
Infectious disease	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transcription by RNA polymerase II	6
DNA-templated transcription	4
regulation of DNA-templated transcription	3
regulation of transcription by RNA polymerase II	2
negative regulation of macromolecule biosynthetic process	2
transcription initiation at RNA polymerase II promoter	2
nuclear receptor binding	2
cellular anatomical structure	2
RNA polymerase II, holoenzyme	2
RNA polymerase II transcription regulator complex	2
negative regulation of DNA-templated transcription	1
polyamine transport	1
DNA repair	1
regulation of DNA metabolic process	1
regulation of cellular response to stress	1
cellular component organization	1
RNA biosynthetic process	1
DNA-templated transcription initiation	1
negative regulation of protein phosphorylation	1
protein kinase activity	1
negative regulation of kinase activity	1
regulation of protein kinase activity	1
nuclear receptor-mediated steroid hormone signaling pathway	1
mRNA transcription	1
MHC class I biosynthetic process	1
regulation of MHC class I biosynthetic process	1
MHC class II biosynthetic process	1
regulation of MHC class II biosynthetic process	1
negative regulation of RNA biosynthetic process	1
positive regulation of RNA biosynthetic process	1
positive regulation of DNA-templated transcription	1
transcription preinitiation complex assembly	1
positive regulation of transcription by RNA polymerase II	1
regulation of transcription initiation by RNA polymerase II	1
positive regulation of DNA-templated transcription initiation	1
transcription regulatory region nucleic acid binding	1
sequence-specific double-stranded DNA binding	1
RNA polymerase II general transcription initiation factor binding	1
general transcription initiation factor activity	1
enzyme binding	1

Protein interactions and networks

STRING

1094 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TAF7	TAF1	P21675	995
TAF7	TAF2	Q6P1X5	975
TAF7	TAF6	P49848	950
TAF7	TAF12	Q16514	946
TAF7	TBP	P20226	930
TAF7	TAF9	Q16594	900
TAF7	TAF8	Q7Z7C8	880
TAF7	TAF10	Q12962	869
TAF7	TAF5	Q15542	868
TAF7	GTF2F1	P35269	857
TAF7	TAF4	O00268	841
TAF7	GTF2B	Q00403	823
TAF7	GTF2F2	P13984	817
TAF7	TAF11	Q15544	796
TAF7	TAF13	Q15543	770

IntAct

79 interactions, top by confidence:

A	B	Type	Score
TAF1	TBP	psi-mi:“MI:0915”(physical association)	0.890
TAF10	TBP	psi-mi:“MI:0914”(association)	0.840
TAF12	TAF4	psi-mi:“MI:0914”(association)	0.760
TBP	TAF4	psi-mi:“MI:0914”(association)	0.730
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
TAF10	TAF4	psi-mi:“MI:0914”(association)	0.650
TBP	TAF7	psi-mi:“MI:0914”(association)	0.640
Taf1	TAF7	psi-mi:“MI:0407”(direct interaction)	0.560
Taf1	TAF7	psi-mi:“MI:0217”(phosphorylation reaction)	0.560
TAF7	TFF2	psi-mi:“MI:0915”(physical association)	0.560
TAF7	UNG	psi-mi:“MI:0915”(physical association)	0.560
TAF7	PABIR3	psi-mi:“MI:0915”(physical association)	0.560
IL20RA	UPK3BL1	psi-mi:“MI:0914”(association)	0.530
TAF8	TAF4	psi-mi:“MI:0914”(association)	0.530
TRAC	COCH	psi-mi:“MI:0914”(association)	0.530
SPATA25	TAF4	psi-mi:“MI:0914”(association)	0.530

BioGRID (165): TAF7 (Protein-peptide), TAF7 (Affinity Capture-MS), TAF7 (Affinity Capture-MS), TAF7 (Affinity Capture-MS), TAF7 (Co-fractionation), TAF7 (Co-fractionation), TAF7 (Affinity Capture-MS), TAF7 (Affinity Capture-MS), TAF7 (Affinity Capture-MS), TAF7 (Affinity Capture-MS), TAF7 (Affinity Capture-MS), TAF7 (Affinity Capture-MS), TAF7 (Affinity Capture-MS), TAF7 (Affinity Capture-MS), TAF7 (Affinity Capture-MS)

ESM2 similar proteins: A0A096LP55, A0A1D8PJT8, A1L243, A1L3N6, A6H767, A9ULB4, P00126, P00429, P05067, P07919, P08592, P12023, P13805, P14854, P23025, P27088, P28656, P36233, P36378, P48504, P55209, P56277, P79307, P99028, Q0P451, Q0VBY0, Q15545, Q28CA1, Q28EB4, Q2HJG8, Q4R374, Q4R5A5, Q4U0Y4, Q53CG4, Q5IS80, Q5M9I5, Q5R4D4, Q5R7L9, Q5RCT0, Q64267

Diamond homologs: B9DG24, Q15545, Q2HJG8, Q4R5A5, Q5H9L4, Q5R7L9, Q6R1L1, Q9D3R9, Q9R1C0, Q9VHY5, O13701, Q05021

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
TAF7	“form complex”	TFIID	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 71 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
HIV Transcription Initiation	9	43.7×	3e-11
RNA Polymerase II HIV Promoter Escape	9	43.7×	3e-11
RNA Polymerase II Promoter Escape	9	43.7×	3e-11
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening	9	43.7×	3e-11
RNA Polymerase II Transcription Initiation	9	43.7×	3e-11
RNA Polymerase II Transcription Initiation And Promoter Clearance	9	43.7×	3e-11
Transcription of the HIV genome	10	36.0×	3e-11
Late Phase of HIV Life Cycle	9	31.5×	4e-10

GO biological processes:

GO term	Partners	Fold	FDR
transcription initiation at RNA polymerase II promoter	8	52.6×	4e-10
RNA polymerase II preinitiation complex assembly	11	52.5×	6e-14
positive regulation of transcription initiation by RNA polymerase II	10	47.7×	2e-12
mRNA transcription by RNA polymerase II	8	46.4×	8e-10
transcription by RNA polymerase II	9	11.1×	1e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

42 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	42
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

354 predictions. Top by Δscore:

Variant	Effect	Δscore
5:141320516:A:AC	donor_gain	0.9100
5:141320517:C:CC	donor_gain	0.9100
5:141320516:ACAAT:A	donor_gain	0.8900
5:141320517:CAATC:C	donor_gain	0.8900
5:141320106:C:CC	acceptor_gain	0.8800
5:141320517:CAAT:C	donor_gain	0.8600
5:141320103:CTA:C	acceptor_gain	0.8300
5:141320656:C:CT	donor_gain	0.7500
5:141320657:T:TT	donor_gain	0.7500
5:141319750:C:CC	acceptor_gain	0.7400
5:141319764:ATCTG:A	acceptor_gain	0.7400
5:141319766:C:A	acceptor_gain	0.7300
5:141320104:TA:T	acceptor_gain	0.7300
5:141320517:CA:C	donor_gain	0.7000
5:141319762:GCATC:G	acceptor_gain	0.6700
5:141320105:A:C	acceptor_gain	0.6700
5:141320114:GTTT:G	acceptor_gain	0.6700
5:141319722:TCC:T	acceptor_gain	0.6400
5:141319765:TCTG:T	acceptor_gain	0.6400
5:141319724:C:CT	acceptor_gain	0.6300
5:141319749:A:AC	acceptor_gain	0.6300
5:141320517:CAA:C	donor_gain	0.6200
5:141320509:GGTAC:G	donor_loss	0.6100
5:141320510:GTAC:G	donor_loss	0.6100
5:141320511:TAC:T	donor_loss	0.6100
5:141320512:ACTTA:A	donor_loss	0.6100
5:141320513:CT:C	donor_loss	0.6100
5:141320514:T:TG	donor_loss	0.6100
5:141320515:T:TC	donor_loss	0.6100
5:141320516:A:AT	donor_loss	0.6100

AlphaMissense

2339 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:141319878:A:T	V56D	1.000
5:141319884:C:T	G54E	1.000
5:141319504:A:G	W181R	0.999
5:141319504:A:T	W181R	0.999
5:141319519:C:G	A176P	0.999
5:141319536:A:G	L170P	0.999
5:141319539:A:G	L169S	0.999
5:141319542:C:G	R168P	0.999
5:141319599:C:G	R149P	0.999
5:141319601:G:C	F148L	0.999
5:141319601:G:T	F148L	0.999
5:141319602:A:G	F148S	0.999
5:141319603:A:G	F148L	0.999
5:141319604:C:A	R147S	0.999
5:141319604:C:G	R147S	0.999
5:141319605:C:A	R147M	0.999
5:141319605:C:G	R147T	0.999
5:141319641:C:T	G135E	0.999
5:141319642:C:G	G135R	0.999
5:141319642:C:T	G135R	0.999
5:141319780:C:G	A89P	0.999
5:141319789:A:C	Y86D	0.999
5:141319811:T:A	K78N	0.999
5:141319811:T:G	K78N	0.999
5:141319817:G:C	S76R	0.999
5:141319817:G:T	S76R	0.999
5:141319819:T:G	S76R	0.999
5:141319885:C:G	G54R	0.999
5:141319885:C:T	G54R	0.999
5:141319104:A:G	L314P	0.998

dbSNP variants (sampled 300 via entrez): RS1000278832 (5:141318805 T>C), RS1001002787 (5:141322489 C>T), RS1001638442 (5:141318207 A>G), RS1002930624 (5:141318566 G>C), RS1003295342 (5:141318293 A>G), RS1003706308 (5:141322002 C>A,T), RS1004510328 (5:141322039 A>T), RS1004624903 (5:141321819 A>C,G,T), RS1004850466 (5:141321553 C>G), RS1004986054 (5:141321219 G>A), RS1008029371 (5:141318133 G>A), RS1008106969 (5:141319918 G>A), RS1010751721 (5:141318064 G>A), RS1011093099 (5:141322012 C>T), RS1011125618 (5:141322275 T>A,C)

Disease associations

OMIM: gene MIM:600573 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST004599_36	Mean platelet volume	2.000000e-10
GCST010002_39	Refractive error	2.000000e-14
GCST90002395_463	Mean platelet volume	2.000000e-15

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

48 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases abundance, increases expression	3
Tobacco Smoke Pollution	increases expression	3
Arsenic	affects methylation, decreases expression, increases abundance	2
Valproic Acid	affects expression, decreases expression	2
Zinc	affects cotreatment, increases expression, decreases expression	2
aristolochic acid I	increases expression	1
FR900359	increases phosphorylation	1
TAK-243	increases sumoylation	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
zinc chromate	increases abundance, increases expression	1
manganese chloride	decreases expression, increases abundance	1
cupric oxide	increases expression	1
resorcinol	increases expression	1
beta-methylcholine	affects expression	1
chromium hexavalent ion	increases abundance, increases expression	1
deguelin	increases expression	1
abrine	increases expression	1
(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II)	increases expression	1
picoxystrobin	increases expression	1
PCI 5002	affects cotreatment, increases expression	1
Acetaminophen	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Ethanol	decreases expression	1
Antimycin A	increases expression	1
Caffeine	decreases phosphorylation	1
Carbamazepine	affects expression	1
Chromium	decreases expression	1
Copper	affects binding, decreases expression	1
Dinitrofluorobenzene	increases expression	1

Cellosaurus cell lines

4 cell lines: 3 embryonic stem cell, 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A6Z3	SEES3-1V human TAF7, clone1	Embryonic stem cell	Male
CVCL_A6Z4	SEES3-1V human TAF7, clone2	Embryonic stem cell	Male
CVCL_A6Z5	SEES3-1V human TAF7, clone3	Embryonic stem cell	Male
CVCL_AW44	K562 eGFP-TAF7	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.